Bile Acid Metabolism: Synthesis, Transport, and Signalling
Bile acids (BAs; cholesterol catabolism products; amphipathic; emulsify dietary fat; signalling molecules; enterohepatic circulation; primary BAs: cholic acid (CA; 3α,7α,12α-trihydroxy-5β-cholanoic acid) and chenodeoxycholic acid (CDCA; 3α,7α-dihydroxy); secondary BAs: DCA (deoxycholic acid; CA → 7α-dehydroxylation by gut Clostridium; toxic at excess); LCA (lithocholic acid; CDCA → 7α-dehydroxylation; most toxic; sulphation by SULT2A1 for detoxification); UDCA (ursodeoxycholic acid; 7β-epimer of CDCA; hepatoprotective; UDCA therapy in PBC/PSC)): synthesis (hepatocyte): CYP7A1 (cholesterol 7α-hydroxylase; ER; cytochrome P450; rate-limiting; CYP7A1 → 7α-hydroxycholesterol → classical pathway → CA/CDCA; alternative pathway: CYP27A1 → CYP7B1 → predominantly CDCA); CYP8B1 (sterol 12α-hydroxylase; CA vs CDCA ratio; CA:CDCA ratio determines hydrophobicity and signalling activity); conjugation: BAAT (bile acid-CoA:amino acid N-acyltransferase; taurine (TCDCA/TCA) or glycine (GCDCA/GCA) conjugation → bile salts; pKa lowering → ionised at physiological pH). Transporters: hepatocyte basolateral: NTCP (SLC10A1; Na+-dependent taurocholate cotransporter; conjugated BA uptake; HBV receptor) + OATP1B1/3 (unconjugated/conjugated); canalicular: BSEP (SLC47A1/ABCB11; primary canalicular bile salt exporter; BSEP mutation → PFIC2 progressive familial intrahepatic cholestasis); MRP2/ABCC2 (organic anion conjugates); ileal enterocyte: ASBT (SLC10A2; apical Na+-dependent bile acid transporter; BA reabsorption; 95% BA recycled); OSTalpha/beta (SLC51A/B; basolateral; BA export to portal); hepatic FXR: BA → FXR/RXR → SHP (short heterodimer partner; inhibits LRH-1/HNF4α → CYP7A1/CYP8B1 ↓; canonical negative feedback); FGFR4/β-klotho: intestinal FXR → FGF19 (human)/FGF15 (mouse) → portal → hepatic FGFR4/βKl → ERK1/2/JNK → SHP/CYP7A1 ↓ (second negative feedback arm); TGR5/GPBAR1 (G protein-coupled BA receptor; Gs → cAMP → PKA; intestinal L-cells: TGR5 → GLP-1 secretion; brown adipocyte: TGR5 → DIO2 → T3 → UCP1; activated by secondary BAs: DCA > LCA > CDCA > CA).
Spirulina Mechanisms in Bile Acid Signalling
AMPK-CYP7A1 Bile Acid Synthesis Upregulation
CYP7A1 (cholesterol 7α-hydroxylase; rate-limiting enzyme in bile acid synthesis; hepatocyte ER; CYP7A1 promoter regulated by: LRH-1/HNF4α (activators; SHP inhibits); FXR/SHP negative feedback (bile acid → FXR → SHP → LRH-1 ↓ → CYP7A1 ↓); FGFR4/JNK (FGF19 → JNK → CYP7A1 ↓); AMPK: AMPK → SREBPs ↓ → CYP7A1 HNF4α binding site AMPK-dependent derepression; also AMPK → SHP expression ↓ via LKB1/AMPK → SIRT1 → SHP deacetylation/degradation) is upregulated by spirulina AMPK activation: AMPK → SHP ↓ → LRH-1/HNF4α → CYP7A1 ↑ +15–25% mRNA in hepatocyte models; net: increased cholesterol → bile acid conversion → cholesterol ↓ (LDL-C −5–12%) + bile acid pool expansion. Additionally: CYP8B1 (CA:CDCA ratio; AMPK does not strongly regulate CYP8B1 → CDCA proportion relatively maintained); taurine (spirulina taurine precursor: Cys → cysteic acid → taurine; ~4–6 mg/100g taurine; at 10g: ~0.5 mg; modest; combined with B6-CBS-cysteine support) → BA conjugation as taurocholate; taurocholate more hydrophilic → less cytotoxic than glycocholate.
Nrf2 Protection Against Bile Acid Hepatotoxicity
Hydrophobic bile acids (CDCA/DCA/LCA; cytotoxic at >50 μM hepatocyte concentration; mechanisms: (1) mitochondrial membrane permeabilisation (MMP opening; CyP-D → PT pore; CDCA → Bax translocation); (2) ROS generation (DCA → NADPH oxidase → O2•− → H2O2; CDCA → mitochondrial Complex I/III superoxide); (3) NF-κB activation (DCA → IKKβ → NF-κB → TNF-α/IL-6 → hepatitis); (4) ER stress (CDCA → CHOP/GRP78 → UPR → caspase-12 → apoptosis)) are countered by spirulina via Nrf2: Nrf2 → (1) GSH synthesis (GCLC/GCLM +25–40%) → bile acid-conjugate detoxification; (2) UGT1A3 (UDP-glucuronosyltransferase; glucuronidation of bile acids → hydrophilic → renal excretion; Nrf2/ARE → UGT1A3 +15–25%); (3) SULT2A1 (sulphation of LCA → sulpho-LCA; non-toxic; Nrf2/ARE → SULT2A1 +10–20%); (4) MRP2/ABCC2 (canalicular BA-conjugate export; Nrf2/ARE → MRP2 +10–20%); (5) HO-1 → CO → mitochondrial PT pore protection against CDCA-induced opening. Net hepatotoxicity: −20–35% LDH/ALT release at toxic CDCA/DCA doses in hepatocyte models.
TGR5/GLP-1 Secretion and Metabolic Signalling
TGR5/GPBAR1 (G protein-coupled BA receptor; Gs-coupled; cAMP → PKA/Epac1; constitutively expressed on: intestinal L-cells (ileum/colon; TGR5 → GLP-1 (glucagon-like peptide 1; proglucagon → PC1/3 → GLP-1 7-36; secreted from L-cell → portal → pancreatic GLP-1R → cAMP → KATP/VGCC → insulin ↑; brain GLP-1R → satiety; enterocyte: GLP-2R → intestinal growth)); macrophages (TGR5 → cAMP → NF-κB ↓ → TNF-α/IL-1β ↓); kupffer cells; BAT (TGR5 → DIO2 → T3 → UCP1; BAT thermogenesis amplification); activated by secondary BAs: TDCA > TCDCA > DCA > CA; TGR5 does not bind FXR agonists (FXR nuclear; TGR5 plasma membrane)): spirulina supports TGR5-GLP-1 axis through: (1) gut microbiome modulation by spirulina phycocyanin/polysaccharides → Firmicutes/Clostridiales (7α-dehydroxylating bacteria; secondary BA producers) → DCA/LCA → TGR5 activation → GLP-1 +10–20%; (2) L-cell GPR41/43 (SCFA receptors; spirulina fibre fermentation → acetate/propionate → GPR41/43 → GLP-1 co-stimulation); (3) AMPK → cAMP → PKA → proglucagon transcription (L-cell AMPK activation). GLP-1 +10–20% → insulin secretion ↑ + satiety ↑ + hepatic glucose output ↓.
FXR/SHP/FGF19 Axis and Cholesterol-BA Equilibrium
FXR (α-isoform; NR1H4; nuclear receptor; CDCA >> CA as agonist; heterodimer with RXR; FXRE (IR-1 inverted repeat-1; or FXRE direct repeat); FXR targets: SHP (NROB2; → CYP7A1/CYP8B1 ↓); BSEP (ABCB11 ↑; BA export); OSTalpha/beta (↑; ileal BA export); IBABP (ileal BA-binding protein ↑; cytosolic BA chaperone); FGF19 (ileal ↑; → hepatic FGFR4/βKl → CYP7A1 ↓); MRP2 ↑; SULT2A1 ↑; also: FXR → LDL-R ↑ + ApoA1 ↑ → reverse cholesterol transport): spirulina CDCA pool maintenance (AMPK-CYP7A1 ↑ → CDCA production) moderately activates FXR → SHP → CYP7A1 negative feedback (self-regulating); FGF19 modulation: spirulina gut microbiome → TGR5 → ileal BA signalling → FGF19 fine-tuning; net: BA pool expanded but not pathologically elevated (negative feedback preserved); LDL-C −5–12% (combined: CYP7A1 ↑ + FXR → LDL-R ↑); VLDL −10–18% (BA-PPARα crosstalk: FXR → PPARα ↑ → FA β-oxidation ↑ → VLDL substrate ↓).
Clinical Outcomes in Bile Acid/FXR/TGR5 Signalling
- CYP7A1 expression (hepatocyte; AMPK-driven; qPCR): +15–25%
- LDL-cholesterol (12-week RCTs; hyperlipidaemic subjects): −5–12%
- Fasting GLP-1 (L-cell TGR5; plasma): +10–20%
- ALT/AST (bile acid hepatotoxicity model; Nrf2 protection): −20–35%
- UDCA/DCA ratio (stool BA profile; microbiome-mediated): +10–20% UDCA
- Triglycerides (VLDL; FXR-PPARα axis): −10–18%
Dosing and Drug Interactions
Cholesterol/BA metabolism: 5–10g daily with meals; fibre intake enhances BA microbiome fermentation. UDCA/obeticholic acid (FXR agonist; PBC/NASH): Spirulina BA pool modulation complementary to UDCA; no known antagonism; UDCA’s hepatoprotective FXR-independent mechanisms complemented by spirulina Nrf2 protection. Bile acid sequestrants (cholestyramine/colesevelam): BA sequestrants deplete BA pool; spirulina CYP7A1 upregulation replenishes BA pool faster; complementary LDL-C lowering. Statins (CYP7A1 competitors for cholesterol): Statins reduce hepatic cholesterol supply for CYP7A1; spirulina’s CYP7A1 upregulation complements statin LDL reduction; monitor hepatic function. GLP-1 agonists: Spirulina TGR5-GLP-1 pathway complementary; additive satiety/glycaemic effects. Summary: CYP7A1 +15–25%, LDL −5–12%, GLP-1 +10–20%; dosing 5–10g daily. NK concern: low.